Paper Details

  1. Home
  2. Paper Details

Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study.

Author: BertoliniFederica, BonizzoniErminio, BriaEmilio, CarnioSimona, CassanoAlessandra, CavannaLuigi, CelioLuigi, ChiariRita, CogoniAlessio Aligi, CollovàElena, CortinovisDiego, De PlacidoSabino, GernoneAngela, LetiziaAntonietta, MartelliOlga, MisinoAndrea, PetrelliFausto, PilottoSara, PiscontiSalvatore, VittimbergaIsabella, ZanelliFrancesca

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study assessed the impact of emesis on the daily lives of patients receiving DEX-sparing regimens using the FLIE scale, providing additional data on the non-inferiority of DEX-sparing regimens compared to standard DEX use in cisplatin-treated patients.
Paper Details　
Original Abstract of the Article :
The non-inferiority of dexamethasone (DEX) on day 1, with or without low-dose DEX on days 2 and 3, combined with oral NEPA (netupitant/palonosetron), compared with the guideline-consistent use of DEX was demonstrated in cisplatin. Here, we complete the analysis by assessing the impact of emesis on d...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400287/

データ提供：米国国立医学図書館（NLM）

Mitigating the Impact of Chemotherapy-Induced Nausea and Vomiting: NEPA's Role in Enhancing Quality of Life

This study explores the impact of chemotherapy-induced nausea and vomiting (CINV) on patients' daily lives and examines the role of NEPA (netupitant/palonosetron) in mitigating these side effects. This research is like a team of healers seeking to alleviate the suffering of those undergoing a challenging medical journey. The authors investigate the effectiveness of NEPA, a combination drug, in reducing CINV and its effects on patients' ability to function, revealing how it can improve quality of life during cancer treatment.

NEPA: A Beacon of Hope for Managing CINV

The study's findings suggest that NEPA, when combined with dexamethasone, can be a valuable tool for reducing CINV and its impact on patients' daily lives. This discovery is like finding a hidden oasis in the desert of chemotherapy side effects, offering relief and improving the overall well-being of patients. The research highlights the importance of addressing CINV to enhance patients' quality of life during cancer treatment.

Navigating the Desert of Chemotherapy Side Effects

This research underscores the significance of developing effective strategies for managing chemotherapy-induced nausea and vomiting. The authors emphasize the need for continued research and development of new therapies, like NEPA, to improve the quality of life of cancer patients. This study serves as a reminder that the fight against cancer requires comprehensive care that addresses not only the disease but also its associated side effects.

Dr.Camel's Conclusion

This study highlights the importance of managing chemotherapy-induced nausea and vomiting to improve the overall quality of life of cancer patients. The findings suggest that NEPA can be a valuable tool for reducing CINV and its impact on patients' daily lives. This research underscores the need for continued exploration and innovation in the fight against cancer, striving to alleviate suffering and improve the well-being of those facing this challenging disease.

Date :
  1. Date Completed 2022-08-25
  2. Date Revised 2022-08-27
Further Info :

Pubmed ID

35999527

DOI: Digital Object Identifier

PMC9400287

Related Literature

Article Analysis
・Effects of netupitant and palonosetron
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.